Skip to main navigation Skip to search Skip to main content

Improving treatment of chromoblastomycosis: the potential of COP1T-HA and antimicrobial photodynamic therapy against Fonsecaea monophora in vitro

  • Xinyao Liu
  • , Zhi Zhang
  • , Jitong Sun
  • , Renjie Fang
  • , Xin Ran
  • , Yuzhou Liu*
  • , Yuping Ran*
  • *Corresponding author for this work
  • Sichuan University
  • Shenyunzhihe Company

Research output: Contribution to journalArticlepeer-review

Abstract

Fonsecaea monophora is one of the common pathogenic species of Chromoblastomycosis (CBM). Antimicrobial photodynamic therapy (aPDT) shows promise as a new treatment for CBM. In this study, we evaluated the effectiveness of COP1T-HA which is a porous organic cage and aPDT against Fonsecaea spp. in vitro.

Original languageEnglish
Pages (from-to)413-417
Number of pages5
JournalMycology
Volume16
Issue number1
DOIs
StatePublished - 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • COP1T-HA
  • Chromoblastomycosis (CBM)
  • Fonsecaea monophora
  • antimicrobial photodynamic therapy (aPDT)

Fingerprint

Dive into the research topics of 'Improving treatment of chromoblastomycosis: the potential of COP1T-HA and antimicrobial photodynamic therapy against Fonsecaea monophora in vitro'. Together they form a unique fingerprint.

Cite this